MARKET

MURA

MURA

Mural Oncology PLC
NASDAQ
2.040
+0.010
+0.49%
Suspension 18:52 12/04 EST
OPEN
2.030
PREV CLOSE
2.040
HIGH
2.040
LOW
2.030
VOLUME
127.78K
TURNOVER
0
52 WEEK HIGH
4.740
52 WEEK LOW
0.9500
MARKET CAP
35.38M
P/E (TTM)
-0.2944
1D
5D
1M
3M
1Y
5Y
1D
Mural Oncology Announces Sanction of the Scheme by the High Court
Barchart · 1d ago
Weekly Report: what happened at MURA last week (1124-1128)?
Weekly Report · 4d ago
Mural Oncology Shareholders To Receive $2.035 Cash Per Share In XOMA Royalty Acquisition
NASDAQ · 11/28 09:55
Mural Oncology announces final cash consideration payable on acquisition close
TipRanks · 11/26 14:05
Mural Oncology Shareholders To Receive $2.035 Per Share As XOMA Royalty Acquisition; Set To Close In Early December 2025
Benzinga · 11/26 14:03
Mural Oncology Sets Final Cash Consideration at $2.035 Per Share in XOMA Royalty Acquisition
Reuters · 11/26 14:00
MURAL ONCOLOGY PLC - TOTAL CASH CONSIDERATION OF $2.035 PER SHARE
Reuters · 11/26 14:00
Weekly Report: what happened at MURA last week (1117-1121)?
Weekly Report · 11/24 09:43
More
About MURA
Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.

Webull offers Mural Oncology PLC stock information, including NASDAQ: MURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MURA stock methods without spending real money on the virtual paper trading platform.